Deborah Henry
Medical · South Sioux City, NENPI 1588751689
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 279 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,637 and has fallen 98.2% since, to $30 in 2024.
Across 279 payments — averaging $11.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$343
- Novo Nordisk$308
- AbbVie$282
- GSK$249
- Bayer$209
- Merck$197
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,214100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 39 | $343 |
| Novo Nordisk | 26 | $308 |
| AbbVie | 29 | $282 |
| GSK | 39 | $249 |
| Bayer | 13 | $209 |
| Merck | 13 | $197 |
| Boehringer Ingelheim | 15 | $192 |
| Amgen | 16 | $180 |
| Pfizer | 16 | $172 |
| Esperion Therapeutics, Inc. | 15 | $155 |
| Sanofi-aventis U.S. LLC | 8 | $150 |
| AstraZeneca | 5 | $138 |
| Radius Health, Inc. | 8 | $109 |
| Amarin Pharma, Inc. | 7 | $95 |
| Novartis | 7 | $91 |
| Organon | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Astellas Pharma US Inc | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Antares Pharma, Inc. | 2 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $24 |
| Abbott | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Johnson & Johnson | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Eisai Inc. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $9 |
How this compares
$3,226 in reported general payments places this provider in the 80th percentile of 216 medical providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $7,401 |
| Paliperidone ErPaliperidone | 12 | $4,480 |
| Atorvastatin Calcium | 13 | $183 |
| Montelukast Sodium | 12 | $159 |
| Metformin Hcl | 13 | $129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $172 | $7,40126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 216 medical providers in Nebraska.
Other medical in South Sioux City
- Michelle SitzmanLincoln$206K
- Kaitlin MatthesLincoln$98K
- Kelly HooverOmaha$16K
- Lyndsey DegenhardtElkhorn$12K
- Jacob RidderOmaha$12K
- Angelika StevensOmaha$8K
- Jennelea MontanezOmaha$8K
- Shannon BusterPapillion$8K
- Jay ArthurLincoln$8K
- Carmen MagistroBellevue$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.